Plain-English translation of NCT06582706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing nicotinic acid, a B vitamin, as a potential treatment for Alzheimer's disease. Researchers believe this medication may help protect brain cells and reduce the buildup of harmful proteins that damage memory and thinking. Half of the participants will receive the treatment, and half will receive a placebo (inactive pill) to see if the medication truly makes a difference.
People who eat more niacin-rich foods tend to have better memory as they age, and this medication has shown promise in early research for slowing brain damage in Alzheimer's. Since this treatment is already FDA-approved and considered safe for other conditions, researchers want to test whether it can help Alzheimer's patients specifically.
You likely qualify if…
You likely don't qualify if…
You will come to the research clinic for an initial visit and then return after 30 days (for a pill count to check you're taking your medication as prescribed) and at the end of the 60-day study. Each day, you'll take one pill either of the medication or placebo at the same time every morning. The study team will collect your pill bottle and count any remaining pills at the end to confirm you've been taking the treatment as directed.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States